In vivo activity of mutacin B-Ny266

Mota‐Meira, Marilaine; Morency, Hélène; Lavoie, Marie

doi:10.1093/jac/dki295

Cited by 84 publications

(45 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, the identification of bacteriocin-mediated probiotic protection could aid the development of alternative bacteriocin-based therapies. It is interesting in this regard that a recent study by Mota-Meira et al (20) demonstrated that mice infected i.p. with Staphylococcus aureus and subsequently injected with mutacin, a bacteriocin produced by S. mutans, are protected from subsequent bacterial challenge.…”

Section: Discussionmentioning

confidence: 99%

Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118

Corr

Li²,

Riedel³

et al. 2007

Proc. Natl. Acad. Sci. U.S.A.

715

464

View full text Add to dashboard Cite

The mechanisms by which probiotic strains enhance the health of the host remain largely uncharacterized. Here we demonstrate that Lactobacillus salivarius UCC118, a recently sequenced and genetically tractable probiotic strain of human origin, produces a bacteriocin in vivo that can significantly protect mice against infection with the invasive foodborne pathogen Listeria monocytogenes. A stable mutant of Lb. salivarius UCC118 that is unable to produce the Abp118 bacteriocin also failed to protect mice against infection with two strains of L. monocytogenes, EGDe and LO28, confirming that bacteriocin production is the primary mediator of protection against this organism. Furthermore, Lb. salivarius UCC118 did not offer any protection when mice were infected with a strain of L. monocytogenes expressing the cognate Abp118 immunity protein AbpIM, confirming that the antimicrobial effect is a result of direct antagonism between Lb. salivarius and the pathogen, mediated by the bacteriocin Abp118.infection ͉ Listeria ͉ probiotic

show abstract

Section: Discussionmentioning

confidence: 99%

Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118

Corr

Li²,

Riedel³

et al. 2007

Proc. Natl. Acad. Sci. U.S.A.

715

464

View full text Add to dashboard Cite

show abstract

“…Antagonistic activity of the bacteriocin producers against a number of pathogenic or antibiotic-resistant bacterial strains in the gut has been a major focus of gut microbiota studies. Several LAB bacteriocins and/or bacteriocin-producing LAB have been shown to inhibit pathogens such as Listeria monocytogenes [83,84], Clostridium difficile [85–87], Staphylococcus aureus [88] and even Salmonella enteritidis [89], Some bacteriocin producers have also been reported to eliminate multidrug- or vancomycin-resistant enterococci [81,90]. Therefore, the production of bacteriocins may contribute to the beneficial activities in the gut.…”

Section: Bacteriocinsmentioning

confidence: 99%

Modulation of the gut microbiota by prebiotic fibres and bacteriocins

Umu

Rudi

Diep

2017

Microbial Ecology in Health and Disease

View full text Add to dashboard Cite

The gut microbiota is considered an organ that co-develops with the host throughout its life. The composition and metabolic activities of the gut microbiota are subject to a complex interplay between the host genetics and environmental factors, such as lifestyle, diet, stress and antimicrobials. It is evident that certain prebiotics, and antimicrobials produced by lactic acid bacteria (LAB), can shape the composition of the gut microbiota and its metabolic activities to promote host health and/or prevent diseases. In this review, we aim to give an overview of the impact of prebiotic fibres, and bacteriocins from LAB, on the gut microbiota and its activities, which affect the physiology and health of the host. These represent two different mechanisms in modulating the gut microbiota, the first involving exploitative competition by which the growth of beneficial bacteria is promoted and the latter involving interference competition by which the growth of pathogens and other unwanted bacteria is prevented. For interference competition in the gut, bacteriocins offer special advantages over traditional antibiotics, in that they can be designed to act towards specific unwanted bacteria and other pathogens, without any remarkable collateral effects on beneficial microbes sharing the same niche.

show abstract

“…However, studies with purified substances have in many cases failed to confirm toxicity (Braude & Siemienski, 1965;Tagg et al, 1976). Although intraperitoneal injection of 10 mg mutacin B-Ny266 kg 21 did not apparently affect the health of mice, these results will have to be confirmed with more relevant toxicity tests (Mota-Meira et al, 2005). The investigation of the in vitro cytotoxicities of two bacteriocins, gallidermin (Staphylococcus gallinarum) and nisin A, in comparison with those of antimicrobial peptides of eukaryotic origin, magainin I, magainin II and melittin, indicated that gallidermin was the least cytotoxic antimicrobial peptide, followed by nisin A, magainin I, magainin II and melittin.…”

Section: Bacteriocin Therapymentioning

confidence: 95%